The HumiraLOE date, referring to the date of Loss of Exclusivity, is a key factor in when generic versions of the drug can enter the market.
When Does Humira's Exclusivity End?
Humira (adalimumab) has faced multiple patent challenges and settlements, leading to a staggered Loss of Exclusivity (LOE) for different markets. In the United States, the primary LOE occurred on February 8, 2023 [1]. This date allowed for the launch of the first interchangeable biosimil versions of adalimumab [2].
Who is Launching Humira Biosimilars?
Following the February 2023 LOE, several companies have launched adalimumab biosimilars in the U.S. These include Amgen, Sandoz, and Boehringer Ingelheim, among others [2]. These biosimilars offer alternatives to the originator product, potentially impacting pricing and market access [2].
How Do Humira Biosimilars Compare?
Biosimilars are highly similar to the reference product in terms of safety, purity, and potency. Adalimumab biosimilars are designed to be administered in the same way as Humira and are indicated for the same medical conditions [3]. Interchangeable biosimilars, like those that launched in February 2023, can be substituted for Humira by a pharmacist without prescriber intervention, similar to generic drugs [2].
What is the Regulatory Pathway for Biosimilars?
In the United States, biosimilars are regulated by the Food and Drug Administration (FDA) under the BPCIA (Biologics Price Competition and Innovation Act). The FDA determines whether a biosimilar is "highly similar" to the reference biologic and whether there are no clinically meaningful differences [3]. For a biosimilar to be deemed "interchangeable," it must undergo additional data requirements to demonstrate that it can be substituted [3].
What Are the Expected Impacts of Humira Biosimilar Entry?
The introduction of biosimilars for a blockbuster drug like Humira is anticipated to increase competition and potentially lower treatment costs for patients and healthcare systems [1][2]. This increased competition can lead to greater patient access to biologic therapies [3].
Where Can I Find More Information on Drug Patents?
Information on drug patent expiries and biosimilar timelines can be found on resources like DrugPatentWatch.com [1]. This site tracks patent statuses and provides data on exclusivity periods for various pharmaceuticals.